Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

ARWR

शेयरों में रैंक #2430
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena,... Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
शेयर मूल्य
$56.99
अंतिम समन्वयन: 2026-10-19
मार्केट कैप
$8.05B
बदलाव (1 दिन)
1.95%
बदलाव (1 वर्ष)
48.14%
देश
US
व्यापार Arrowhead Pharmaceuticals, Inc. (ARWR)

श्रेणी

Healthcare
Arrowhead Pharmaceuticals, Inc. (ARWR) के लिए लाभांश इतिहास
Arrowhead Pharmaceuticals, Inc. (स्टॉक चिन्ह: ARWR) ने कुल 0 लाभांश भुगतान किए।
सभी लाभांशों का योग (स्टॉक स्प्लिट्स के लिए समायोजित) है: 0.00
लाभांश यील्ड (TTM): 0
Arrowhead Pharmaceuticals, Inc. (ARWR) के लिए 2026 से 2026 तक के लाभांश भुगतान
वार्षिक लाभांश भुगतान
वर्ष लाभांश (स्टॉक स्प्लिट समायोजित) परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
सभी लाभांश भुगतानों की सूची
वर्ष लाभांश परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतिस्पर्धियों के लाभांश भुगतान
कंपनी लाभांश भुगतान की संख्या देश
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL